metaLinear focuses on the identification and validation of new drug targets for difficult to treat bacterial infections.metaLinear uses a proprietary proteome engineering platform technology to uncover, characterise and validate new targets for antibiotics. Using very large libraries of Randomised proteins (R-teins) expressed in target bacteria,metaLinear will screen for novel targets responsible for the desired phenotype. A key advantage of this approach is the ability to de-risk targets and hence provide multiple efficiency gains in the traditional target and drug discovery process.

metaLinear

Similar companies